---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Psychotropic medications for anxiety and behavior"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Psychotropic medications for anxiety and behavior. Topics: Consensus guideline: screening for anxiety and depression and selective serotonin reuptake inhibitors, Natural History Study: absence of anxiety management guidelines, Natural History Study: frequency of anxiolytic and SSRI use, and Natural History Study: efficacy and safety not assessed. 4 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/psychotropic-medications-for-anxiety-and-behavior"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Psychotropic medications for anxiety and behavior

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Psychotropic Medications for Anxiety and Behavior

<a id="topic-2.2.2.1.6-1"></a>

### Consensus guideline: screening for anxiety and depression and selective serotonin reuptake inhibitors

> “Screen for caregiver impressions of anxiety and depression, such as withdrawal; these may become more prominent with age or in individuals with milder clinical presentations. Identify possible contributors (eg, sedating medications, decreased social interaction, limited access to engaging activities). Consider treatment with a selective serotonin reuptake inhibitor such as escitalopram which may have a lower risk of inducing a prolonged QTc interval.”
> “Families should be encouraged to disclose use of alternative medications (cannabis, oils and so on) to all specialists.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.6-2"></a>

### Natural History Study: absence of anxiety management guidelines

> “In spite of the general impression that anxiety-like behavior is common in individuals with RTT, no systematic studies of anxiolytics use have been reported in this population and guidelines for clinical management of anxiety in RTT do not exist.”

Source: [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/)

<a id="topic-2.2.2.1.6-3"></a>

### Natural History Study: frequency of anxiolytic and SSRI use

> “Parental reports and medication logs provided data from 1380 females with RTT participating in two iterations of the multicenter U.S. RTT Natural History Study (RNHS) from 2006 to 2019.”
> “Parents directly reported treatment for anxious or nervous behavior in 16.6% of participants in the second iteration with most reporting good control of the behavior (71.6%).”
> “15.0% of participants in the first and 14.5% in the second (P = 0.835). The most commonly used drugs were escitalopram, sertraline, fluoxetine, and buspirone.”
> “Based on medication logs, SSRI use for any indication was reported for 13.1% of participants in the first iteration and 11.0% in the second iteration (P = 0.414).”
> “Increased use of anxiolytics and selective serotonin reuptake inhibitors (SSRIs) was related to more frequent anxiety-like behaviors (P < 0.001), older age (P < 0.001), and mild MECP2 variants (P = 0.002).”

Source: [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/)

<a id="topic-2.2.2.1.6-4"></a>

### Natural History Study: efficacy and safety not assessed

> “The present study was not designed to assess the efficacy or safety of these medications, but parent report indicates that most treated participants have good control.”

Source: [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
